A comprehensive view of Shionogi & Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

ViiV Healthcare's long-acting injectable antiretroviral treatment for HIV, Cabenuva, shows superior efficacy in maintaining viral load suppression compared to daily oral therapy; results come from interim results from Phase 3 trial
Published: February 21, 2024 by GSK Group (GlaxoSmithKline)
China approves ViiV Healthcare's injectable HIV treatment consisting of Vocabria cabotegravir and Janssen's Rekambys rilpivirine; HIV affects over 1 million people in China
Published: October 27, 2023 by Targeted News Service (Press Releases)
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at 19th Annual European AIDS Conference in Warsaw, Poland from October 18-21
Published: October 18, 2023 by M2 PressWIRE
European Medicines Agency gives positive opinion for marketing authorization of ViiV Healthcare's cabotegravir, an injectable and tablet for HIV prevention; ViiV Healthcare is owned by GSK as a majority shareholder, along with Pfizer and Shionogi & Co
Published: July 24, 2023 by Alliance News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count